Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;40(10):4421-4439.
doi: 10.1007/s12325-023-02611-0. Epub 2023 Jul 28.

Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease

Brian Bressler  1 , Jennifer Jones  2 , Tracy S H In  3 , Tommy Lan  4 , Cristian Iconaru  4 , John K Marshall  5
Affiliations

Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease

Brian Bressler et al. Adv Ther. 2023 Oct.

Abstract

Introduction: There is an urgent need to understand the long-term real-world effectiveness of ustekinumab (UST) in the treatment of Crohn's disease (CD), fistulizing CD (FCD), and ulcerative colitis (UC). Persistence on treatment is commonly used as a surrogate measure of real-world treatment response. This study aims to estimate the long-term real-world persistence of UST in adult patients with CD, FCD, and UC.

Methods: A retrospective study was conducted in patients with CD, FCD, and UC treated with UST through a national patient support program in Canada. Treatment persistence was described using the Kaplan-Meier method, and the impact of patient characteristics on persistence was explored through stratified analyses and multivariable Cox proportional hazards models.

Results: Persistence rates for 8724 patients with CD were 82.9%, 71.4%, 64.1%, and 59.7% at 1, 2, 3, and 4 years, respectively. Similarly, persistence rates for 276 patients with FCD were 84.1%, 70.9%, 64.9%, and 63.1% at 1, 2, 3, and 4 years, respectively. Persistence rates for 1291 patients with UC were 76.5% at 1 year and 69.5% at 1.5 years. When stratified by prior IBD-indicated biologic experience, persistence was numerically higher in biologic-naïve patients across all disease cohorts. A Cox proportional hazards model confirmed that this difference was significant in patients with CD (hazard ratio: 0.72; confidence interval: [0.65-0.79]).

Conclusions: This study estimated long-term persistence in a large population of patients with IBD. At 1 year, over three-fourths of patients remained on UST treatment in all disease cohorts, and over half of patients remained on treatment at 4 years in CD and FCD patients. Biologic-naïve status was significantly associated with higher persistence in patients with CD.

Keywords: Crohn’s disease; Persistence; Ulcerative colitis; Ustekinumab.

Plain language summary

Inflammatory bowel disease is a term that refers to a group of disorders where the tissues of the gastrointestinal tract are chronically inflamed and may become damaged; it includes Crohn’s disease and ulcerative colitis. While there is no cure, treatments are available to help patients manage their disease. Patients must typically continue treatment to ensure ongoing control. As such, the length of time a patient continues using a specific treatment can be suggestive of its success in the real-world. Ustekinumab is a biologic therapy that is used to treat both Crohn’s disease and ulcerative colitis. Although ustekinumab has been evaluated in clinical trials, understanding how patients respond to treatment in the real world is valuable to physicians. This study was able to look at patients with inflammatory bowel disease who received treatment with ustekinumab through a patient support program in Canada and assess the length of time they continued treatment. After 1 year, over three-fourths of all patients with inflammatory bowel disease were still using ustekinumab; and after 4 years, more than half of patients with Crohn’s disease were still using ustekinumab. This study was also able to look at whether certain factors affected the likelihood of a patient continuing treatment with ustekinumab. Patients that had never received a biologic therapy before were more likely to continue ustekinumab treatment than those who had received a different biologic therapy beforehand.

PubMed Disclaimer

References

    1. Zhou N, Chen WX, Chen SH, Xu CF, Li YM. Inflammatory bowel disease unclassified. J Zhejiang Univ Sci B. 2011;12(4):280–6. - DOI - PubMed - PMC
    1. Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11(2):165–74. - DOI - PubMed
    1. Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(5):e1-10. - DOI - PubMed
    1. Coward SCF, Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Hazlewood G, Jelinski S, Jones J, Kuenzig E, Leddin D, McBrien K, Murthy S, Nguyen GC, Otley A, Rezaie A, Pena-Sanchez J, Singh H, Targownik L, Kaplan GG. A29 the rising prevalence of inflammatory bowel disease in Canada: analyzing the past to predict the future. J Can Assoc Gastroenterol. 2018;1(Suppl 2):47–8. - DOI - PMC
    1. Kaplan GG, Bernstein CN, Coward S, et al. The impact of inflammatory bowel disease in canada 2018: epidemiology. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S6–16. - DOI - PubMed

Publication types

LinkOut - more resources